DHL Supply Chain, which happens to be a German contract logistics service provider, has gone on to launch a novel pharma hub in Singapore. This kind of dedicated facility when it comes to pharmaceutical logistics goes to represent an investment worth $11.37 billion.
This facility is a part of the DHL Group’s broader $568 million commitment when it comes to enhancing its life sciences and healthcare infrastructure throughout all business units across Asia Pacific. It also goes on to depict the firms within healthcare sector as a part of its strategy 2030. Apparently, the life sciences and healthcare infrastructure at present generates $5.68 billion for the global revenue of DHL, thereby highlighting its prominence when it comes to the group’s growth strategy.
The new pharma hub in Singapore, which extends to 8200 km² in Singapore, goes on to feature temperature-controlled areas, thereby creating perfect conditions in order to store delicate medical supplies. This facility, which adheres to the good manufacturing practice – GMP also has in it an advanced cold storage infrastructure like airtight loading docks along with specialized anterooms that make sure of a temperature stability all throughout the transportation process which is consistent in nature.
As per the CEO of Asia Pacific for DHL Supply Chain, Javier Bilbao, their investment goes much beyond building only warehouses or expanding network. It is more like coming up with a robust foundation throughout all the business units that enables faster along with a more dependable delivery when it comes to lifesaving medicines and healthcare products. He adds that in the region where healthcare demand happens to be increasing, they help their customers to stress innovation and, thereby, at the end of the day, patient care.
He further went on to add that at the same time, they handle the intricacies when it comes to supply chain management throughout the logistic touchpoints, right from storage and order fulfillment to spreading throughout worldwide shipping and also last-mile delivery. And that is how they go on to deliver real value by way of turning barriers into opportunities and making sure that every link within the healthcare supply chain works as seamlessly as possible.
It is well to be noted that the pharma hub in Singapore is based at Tuas Bio-Medical Park, hence offering a convenient access to both Tuas Mega Port and Changi Airport in order to elevate distribution capacities for its pharmaceutical partners, both in the region and across the world.
Furthermore, DHL Group has also announced a worldwide investment of $2.27 billion by the end of the decade in order to enhance the integrated healthcare solutions. Apart from this, it has recently acquired CRYOPDP, which is a specialty courier offering end-to-end temperature control solutions and also services that are customized for the life sciences and healthcare sector.